Whitney Ijem
Stock Analyst at Canaccord Genuity
(4.41)
# 334
Out of 5,237 analysts
136
Total ratings
48.31%
Success rate
22.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $140 → $143 | $94.17 | +51.85% | 12 | May 7, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $104 → $116 | $54.06 | +114.58% | 11 | May 7, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $437 → $436 | $429.82 | +1.44% | 12 | May 5, 2026 | |
| WVE Wave Life Sciences | Maintains: Buy | $52 → $43 | $7.18 | +498.89% | 5 | Apr 30, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $48 → $58 | $14.09 | +311.64% | 8 | Apr 28, 2026 | |
| PHAR Pharming Group | Initiates: Buy | $37 | $12.98 | +185.05% | 1 | Apr 10, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $14 → $17 | $6.81 | +149.63% | 12 | Apr 6, 2026 | |
| NGNE Neurogene | Maintains: Buy | $200 → $180 | $30.78 | +484.80% | 2 | Apr 6, 2026 | |
| GUTS Fractyl Health | Maintains: Buy | $8 | $0.75 | +960.02% | 3 | Mar 26, 2026 | |
| OCGN Ocugen | Initiates: Buy | $12 | $1.51 | +694.70% | 1 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $21 | $9.22 | +127.77% | 7 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $23 | $4.21 | +446.32% | 8 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $74 | $32.32 | +128.96% | 1 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $79 | $26.12 | +202.45% | 10 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $415 → $429 | $295.05 | +45.40% | 10 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.00 | +400.00% | 7 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $204 | $121.29 | +68.19% | 8 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $3.63 | +175.48% | 9 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $150 | $19.96 | +651.69% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $131.33 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $120 → $240 | $8.64 | +2,677.78% | 4 | Jul 23, 2019 |
Rhythm Pharmaceuticals
May 7, 2026
Maintains: Buy
Price Target: $140 → $143
Current: $94.17
Upside: +51.85%
BioMarin Pharmaceutical
May 7, 2026
Maintains: Buy
Price Target: $104 → $116
Current: $54.06
Upside: +114.58%
Vertex Pharmaceuticals
May 5, 2026
Maintains: Hold
Price Target: $437 → $436
Current: $429.82
Upside: +1.44%
Wave Life Sciences
Apr 30, 2026
Maintains: Buy
Price Target: $52 → $43
Current: $7.18
Upside: +498.89%
Intellia Therapeutics
Apr 28, 2026
Maintains: Buy
Price Target: $48 → $58
Current: $14.09
Upside: +311.64%
Pharming Group
Apr 10, 2026
Initiates: Buy
Price Target: $37
Current: $12.98
Upside: +185.05%
Taysha Gene Therapies
Apr 6, 2026
Maintains: Buy
Price Target: $14 → $17
Current: $6.81
Upside: +149.63%
Neurogene
Apr 6, 2026
Maintains: Buy
Price Target: $200 → $180
Current: $30.78
Upside: +484.80%
Fractyl Health
Mar 26, 2026
Maintains: Buy
Price Target: $8
Current: $0.75
Upside: +960.02%
Ocugen
Mar 17, 2026
Initiates: Buy
Price Target: $12
Current: $1.51
Upside: +694.70%
Mar 5, 2026
Maintains: Buy
Price Target: $66 → $21
Current: $9.22
Upside: +127.77%
Mar 4, 2026
Maintains: Buy
Price Target: $67 → $23
Current: $4.21
Upside: +446.32%
Feb 20, 2026
Initiates: Buy
Price Target: $74
Current: $32.32
Upside: +128.96%
Feb 18, 2026
Maintains: Buy
Price Target: $128 → $79
Current: $26.12
Upside: +202.45%
Feb 17, 2026
Maintains: Buy
Price Target: $415 → $429
Current: $295.05
Upside: +45.40%
Dec 18, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.00
Upside: +400.00%
Dec 16, 2025
Maintains: Buy
Price Target: $148 → $204
Current: $121.29
Upside: +68.19%
Jul 25, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $3.63
Upside: +175.48%
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $19.96
Upside: +651.69%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $131.33
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $120 → $240
Current: $8.64
Upside: +2,677.78%